Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.47 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9450535 | 0.87 | ACE (0.54) | F2ACESTAT6OPRK1 | |
| SCHEMBL29666779 | 0.85 | ACE (0.62) | F2ACEOPRK1 | |
| SCHEMBL7477934 | 0.84 | ACE (0.56) | F2ACESTAT6OPRK1OPRM1 | |
| SCHEMBL9450538 | 0.83 | ACE (0.54) | F2ACESTAT6OPRK1OPRM1 | |
| SCHEMBL7464019 | 0.82 | ACE (0.53) | F2ACEOPRK1OPRM1 | |
| SCHEMBL7463168 | 0.82 | OPRK1 (0.60) | F2ACEOPRK1OPRM1 | |
| SCHEMBL9710298 | 0.82 | ACE (0.51) | F2ACESTAT6OPRK1 | |
| SCHEMBL9450537 | 0.81 | OPRK1 (0.54) | F2ACESTAT6OPRK1OPRM1 | |
| SCHEMBL7473007 | 0.81 | ACE (0.52) | F2ACESTAT6OPRK1OPRM1 | |
| SCHEMBL31473057 | 0.81 | OPRM1 (0.53) | F2ACEOPRK1OPRM1NMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | F2 3457/4885ACE 1033/4885STAT6 4513/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | F2 3457/4885ACE 1033/4885STAT6 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.